contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


number-of-shares-and-votes-in-nanologica-ab-publ-2

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nanologica is a life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially designed for the purification of peptide drugs, such as insulin and GLP-1 analogs. Nanologica operates in a global niche market for medicines for the treatment of diabetes and obesity. Nanologica was founded in 2004 and has its headquarters in Södertälje.

Nanologica

The number of registered shares and votes in Nanologica AB has changed during the month of November following the registration of parts of the previously communicated rights issue.The rights...

<div class="mfn-preamble"><p><strong>The number of registered shares and votes in Nanologica AB has changed during the month of November following the registration of parts of the previously communicated rights issue.</strong></p></div><div class="mfn-body"><p>The rights issue was subscribed for approximately 87.0 percent with and without the support of unit rights, whereby the underwriting commitment from Flerie Invest AB was used for 1,438,755 units, corresponding to the remaining approximately 13.0 percent of the rights issue. The part of the issue relating to the underwriting commitment was allocated and registered with the Swedish Companies Registration Office in November. This means that during November, the number of shares in Nanologica has increased by 5,755,020 shares from 82,602,214 to 88,357,234 shares and that the share capital has increased by SEK 575,502.0 from SEK 8,260,221.4 to SEK 8,835,723.4.<br>&nbsp;<br>The Extraordinary General Meeting on September 23, 2024, resolved to reduce the share capital by an amount in SEK corresponding to the amount by which the share capital increases through the rights issue (regarding the part where the share capital increase is attributable to a new issue of shares), with relevant adjustments to achieve an appropriate quota value. During November, Nanologica applied for permission from the Swedish Companies Registration Office for a reduction of the share capital by SEK 4,329,504.466, from SEK 8,835,723.4 to SEK 4,506,218.934. Subject to the Swedish Companies Registration Office’s approval which is expected in January at the earliest, the share’s quota value after the reduction will amount to SEK 0.051 per share.<br>&nbsp;<br>As of November 29, 2024, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 88,357,234.</p></div><div class="mfn-footer mfn-contacts mfn-31afac252a6d"><p><strong class="mfn-heading-1">For further information, please contact</strong><br>Johanna Johansson<br>Director IR, Communications and Marketing<br>johanna.johansson@nanologica.com<br>+46 72 211 21 90</p></div><div class="mfn-footer mfn-about mfn-c09c1d849689"><p><strong class="mfn-heading-1">About Nanologica AB (publ)</strong><br>Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit <a rel="noopener" href="http://www.nanologica.com">www.nanologica.com</a>.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>This information is information that Nanologica AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-11-29 10:05 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/1c32da7e-2e7b-48fb-b013-ba4051d37489/number-of-shares-and-votes-in-nanologica-ab-publ.pdf" class="mfn-generated mfn-primary">Number of Shares and Votes in Nanologica AB (publ)</a></p></div>